Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients

Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients

Anemia is a frequent complication in patients with chronic kidney disease. However, human recombinant erythropoietin (rHu-EPO) has revolutionized the management of anemia in chronically dialyzed patients. Epomax ® is a new rHu-EPO alfa manufactured in Tunisia (Medis Laboratories). The aim of this st...

Full description

Bibliographic Details
Main Authors:	Amel Harzallah, Karim Zouaghi, Afef Dridi, Karima Boubaker, Soumaya Beji, Mohamed Ayari, Fethi El Younsi, Fatma Ben Moussa, Adel Kheder
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-01-01
Series:	Saudi Journal of Kidney Diseases and Transplantation
Online Access:	http://www.sjkdt.org/article.asp?issn=1319-2442;year=2015;volume=26;issue=1;spage=78;epage=82;aulast=Harzallah

Similar Items

The use of epoetin alfa biosimilar in the anemia management in hemodialysis patients
by: I. O. Dudar, et al.
Published: (2021-02-01)

Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study
by: Giovanni Rosti, et al.
Published: (2017-01-01)

INFLUENCE OF EPOETIN ALFA ON LEVEL OF PROINFLAMMATORY AND ANTIINFLAMMATORY CYTOKINE OF PATIENTS IN MAINTENCE HEMODIALYSIS
by: I. Dudar, et al.
Published: (2014-03-01)

Epoetin-alfa-induced osteogenesis in the bone organoid model
by: Natalia A. Nadezhdina, et al.
Published: (2024-12-01)

Epoetin Alfa: A Cause of Coronary Artery Thrombosis
by: Muhammad Umer Siddiqui, et al.
Published: (2017-01-01)

Bleeding and Thrombosis in a Patient with Secondary Antiphospholipid Syndrome
by: Kaaroud Hayet, et al.
Published: (2008-01-01)

Comparison Of The Effectiveness And Safety Of Anemia Epoetin Alfa With Epoetin Beta Inhemodialysis Routine Patients At Haji Rsu Surabaya
by: Gunawan Widodo, et al.
Published: (2021-12-01)

THE COMPLEX INTENSIVE THERAPY INCLUDING APPLICATION EPOETIN ALFA AT THE SERIOUS СONCOMITANT BRAIN INJURY
by: E. A. Lebedeva, et al.
Published: (2013-03-01)

Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open‐label, parallel‐group, noninferiority phase III trial
by: Bicheng Liu, et al.
Published: (2022-06-01)

Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail
by: Nan Chen, et al.
Published: (2022-03-01)

Kaposi′s sarcoma with HHV8 infection and ANCA-associated vasculitis in a hemodialysis patient
by: Lilia Ben Fatma, et al.
Published: (2013-01-01)

THE CLINICAL EFFICACY OF EPOETIN ALFA AND DARBEPOETIN ALFA IN PATIENTS WITH LOW-RISK OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROME: RETROSPECTIVE MULTI-CENTER REAL-LIFE STUDY
by: Müzeyyen Aslaner Ak, et al.
Published: (2023-10-01)

Cohort Prospective Study to Evaluate Immunogenicity of Epodion® (Biosimilar Epoetin-α) in Anemia Associated with Chronic Kidney Disease (CKD) Patients
by: Nova Angginy, et al.
Published: (2022-07-01)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
by: November McGarvey, et al.
Published: (2015-11-01)

Comparison of C-reactive protein and high-sensitivity C-reactive protein levels in patients on hemodialysis
by: Imed Helal, et al.
Published: (2012-01-01)

A case of renal granulomatosis with polyangiitis following intravesical bacillus Calmette-Guérin therapy
by: Yosra Selmi, et al.
Published: (2018-01-01)

Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France
by: Matthieu Lehmann, et al.
Published: (2024-06-01)

Social trends in living kidney donors in a single center
by: Lilia Ben Fatma, et al.
Published: (2015-01-01)

The Use of Epoetin-α in Revision Knee Arthroplasty
by: Lawrence A. Delasotta, et al.
Published: (2012-01-01)

Fatigue visual analogue scale score correlates with quality of life in cancer patients receiving epoetin alfa (Sandoz) for chemotherapy-induced anaemia: The CIROCO study
by: Jerome Desramé, et al.
Published: (2023-01-01)

Epstein Syndrome
by: Sana Barrah, et al.
Published: (2020-01-01)

Acute kidney injury with granulomatous interstitial nephritis and vasculitis revealing sarcoidosis
by: Amel Harzallah, et al.
Published: (2017-01-01)

Effect of Sevelamer on Mineral and Lipid Abnormalities in Hemodialysis Patients
by: Hamida Fethi, et al.
Published: (2008-01-01)

Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
by: Nayana Hitesh Patel, et al.
Published: (2023-04-01)

Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®)
by: Z. B. Barakhoeva, et al.
Published: (2018-11-01)

Disseminated cryptococcosis as a complication of lupus nephritis
by: Soumaya Beji, et al.
Published: (2017-01-01)

Incidence and challenges in management of hemodialysis catheter-related infections
by: Meriam Hajji, et al.
Published: (2022-11-01)

Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
Published: (2023-07-01)

Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients
by: Helal Imed, et al.
Published: (2010-01-01)

P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY
by: Uwe Platzbecker, et al.
Published: (2023-08-01)

Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation
by: Giovanni Barosi, et al.
Published: (2011-07-01)

Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis
by: Paulo D. Picon, et al.
Published: (2014-08-01)

A letter to editor – Critical appraisal on “Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.”
by: Juan-Enrique Schwarze, et al.
Published: (2024-09-01)

Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin δ
by: Bruce S. Spinowitz
Published: (2008-05-01)

Topical ocular delivery of nanoparticles with epoetin beta in Wistar Hannover rats
by: Beatriz Silva, et al.
Published: (2023-01-01)

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
by: G. Garcia-Manero, et al.
Published: (2024-01-01)

Methoxy polyethylene glycol epoetin beta and the treatment of anaemia in chronic heart failure
by: K. Kh. Zakhidova, et al.
Published: (2013-06-01)

Chitosan and Hyaluronic Acid Nanoparticles as Vehicles of Epoetin Beta for Subconjunctival Ocular Delivery
by: Beatriz Silva, et al.
Published: (2022-02-01)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
by: Teresa Barcina Lacosta, et al.
Published: (2022-12-01)

S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
by: Matteo Giovanni Della Porta, et al.
Published: (2023-08-01)